Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site

Thoracic Malignancies


Rossana Berardi


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


R. Berardi1, G. Lo Russo2, M. Tiseo3, L. Cavanna4, D. Ferrari5, E. Rijavec6, G. Altavilla7, A. Morabito8, G. Pinotti9, R. Buosi10, M. Scartozzi11, C. Ferrara12, M.G. Giustra12, R. Evans13, V. De Marino14

Author affiliations

  • 1 Clinical Oncology, Dept. Of Internal Medicine, Università Politecnica Marche – Ospedali Riuniti Ancona, 60126 - Ancona/IT
  • 2 Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori Via Giacomo Venezian, 20133 - Milan/IT
  • 3 Medical Oncology, Azienda Ospedaliero-Universitaria di Parma, 43126 - Parma/IT
  • 4 Oncology And Hematology, AUSL di Piacenza, 29100 - Piacenza/IT
  • 5 Medical Oncology, Azienda Ospedaliera San Paolo, 20142 - Milan/IT
  • 6 Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino IST - Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 7 Medical Oncology, Azienda Ospedaliera Universitaria Policlinico G. Martino di Messina, 98125 - Messina/IT
  • 8 Thoracopulmonary, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale, 80131 - Napoli/IT
  • 9 Medical Oncology, Ospedale di Circolo e Fondazione Macchi, 21100 - Varese/IT
  • 10 Oncology, ASL Alessandria Santo Spirito Hospital, 15022 - Casale Monferrato AL/IT
  • 11 Medical Oncology, Policlinico Universitario Duilio Casula, 09042 - Monserrato/IT
  • 12 Medical Affairs, Otsuka Pharmaceutical Italy Srl, 20124 - Milan/IT
  • 13 Medical Affairs, Oncology & Specialty, Otsuka Pharmaceutical Europe Ltd, SL36PJ - Wexham/GB
  • 14 Medical Oncology, Azienda Ospedaliera Specialistica dei Colli "Monaldi – Cotugno – CTO", 80131 - Napoli/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5511


Hyponatremia (serum sodium concentration [Na+] <135 mmol/L), is the most common electrolyte disorder in lung cancer patients (incidence 20–44%) with SIADH a frequent cause, particularly in small cell lung cancer (SCLC).


ASSERT was a prospective, observational, non-interventional study conducted from October 2015 to June 2017 in cancer patients requiring treatment for hyponatremia secondary to SIADH at 18 Italian oncology centres. Management of hyponatremia primarily included water restriction, tolvaptan and hypertonic saline, in accordance with local standard of care/guideline recommendations. The primary endpoint was change in serum [Na+] from baseline visit to end of the first month of the observational period, or earlier discontinuation.


The full analysis set (FAS) included 68 adult cancer patients (lung cancer, n = 48, SCLC, n = 33). Group 1 patients received ≥1 dose of tolvaptan during the observational period; Group 2 patients did not receive tolvaptan. Overall survival (FAS) was significantly higher in Group 1 vs Group 2 (median 123 vs 56 days; p = 0.001), as was mean survival (299.4 vs 74.9 days; p = 0.001). In a linear regression analysis of the relationship between sodium levels and tolvaptan dose intensity for the lung cancer and SCLC cohorts, dose intensity correlated significantly with clinical response after 6 months of treatment in both cohorts (p = 0.005 and p = 0.023, respectively). In the lung cancer cohort, a significantly higher percentage of patients achieved serum [Na+] ≥130 mmol/L in Group 1 vs Group 2 during 6 months of follow-up (Group 1, 87.5% vs Group 2, 62.5%; p = 0.033). These results were similar to those observed in the FAS.


Hyponatremia secondary to SIADH is a potentially modifiable risk factor, which might be implicated in the survival of lung cancer patients. Correction of hyponatremia may be preferentially achieved with pharmacological treatment, rather than the non-pharmacological approaches routinely used in clinical practice.

Clinical trial identification


Editorial acknowledgement

Sarah Stowell PhD, CMPP of Ashley Medical Communications, funded by Otsuka Pharmaceutical Europe Ltd.

Legal entity responsible for the study

Otsuka Pharmaceutical Italy Srl.


Otsuka Pharmaceutical Italy Srl.


R. Berardi: Honoraria (self), Advisory / Consultancy: Otsuka Pharmaceutical. C. Ferrara: Full / Part-time employment: Otsuka Pharmaceutical Italy. M.G. Giustra: Full / Part-time employment: Otsuka Pharmaceutical Italy. R. Evans: Full / Part-time employment: Otsuka Pharmaceutical Europe. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.